Effect of contrast agent on the results of in vivo 1H MRS of breast tumors - is it clinically significant?

NMR in Biomedicine

Volumn 25, Issue 1, 2012, Pages 67-74

  Baltzer, Pascal A T ^a   Gussew, Alexander ^a   Dietzel, Matthias ^a   Rzanny, Reinhard ^a   Gajda, Mieczyslaw ^a   Camara, Oumar ^a   Reichenbach, Jürgen R ^a   Kaiser, Werner A ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER DIAGNOSIS; BREAST TUMOR; CONTRAST AGENT; DIETHYLENETRIAMINE PENTA-ACETIC ACIDS; GROUP MEMBERSHIPS; IN-VIVO; INDEPENDENT PREDICTORS; INFLUENCING FACTOR; MALIGNANT LESION; MALIGNANT TUMORS; MULTI VARIATE ANALYSIS; SIGNAL IDENTIFICATION;

GADOLINIUM; TUMORS;

MULTIVARIANT ANALYSIS;

CHOLINE; GADOLINIUM DIETHYLENETRIAMINEPENTAACETIC ACID BIS METHYLAMIDE; GADOLINIUM PENTETATE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CONTROLLED STUDY; DIAGNOSTIC IMAGING; HUMAN; IN VIVO STUDY; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTON NUCLEAR MAGNETIC RESONANCE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CHOLINE; CONTRAST MEDIA; FEMALE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MIDDLE AGED; PROTONS; REGRESSION ANALYSIS; YOUNG ADULT;

EID: 84855908802     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.1714     Document Type: Article

References (32)

1. Michaelson JS, Silverstein M, Wyatt J, Weber G, Moore R, Halpern E, Kopans DB, Hughes K. Predicting the survival of patients with breast carcinoma using tumor size. Cancer, 2002; 95: 713-723.
2. Kaiser WA, Zeitler E. MR imaging of the breast: fast imaging sequences with and without Gd-DTPA. Preliminary observations. Radiology, 1989; 170: 681-686.
3. Kuhl C. The current status of breast MR imaging. Part I. Choice of technique, image interpretation, diagnostic accuracy, and transfer to clinical practice. Radiology, 2007; 244: 356-378.
4. Mann RM, Kuhl CK, Kinkel K, Boetes C. Breast MRI: guidelines from the European Society of Breast Imaging. Eur. Radiol. 2008; 18: 1307-1318.
5. Baltzer PA, Vag T, Dietzel M, Beger S, Freiberg C, Gajda M, Camara O, Kaiser WA. Computer-aided interpretation of dynamic magnetic resonance imaging reflects histopathology of invasive breast cancer. Eur. Radiol. 2010; 20: 1563-1571.
6. Gutierrez RL, DeMartini WB, Eby PR, Kurland BF, Peacock S, Lehman CD. BI-RADS lesion characteristics predict likelihood of malignancy in breast MRI for masses but not for nonmasslike enhancement. Am. J. Roentgenol. 2009; 193: 994-1000.
7. Sardanelli F, Boetes C, Borisch B, Decker T, Federico M, Gilbert FJ, Helbich T, Heywang-Kobrunner SH, Kaiser WA, Kerin MJ, Mansel RE, Marotti L, Martincich L, Mauriac L, Meijers-Heijboer H, Orecchia R, Panizza P, Ponti A, Purushotham AD, Regitnig P, Del Turco MR, Thibault F, Wilson R. Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group. Eur. J. Cancer, 2010; 46: 1296-1316.
8. Ikeda DM, Hylton NM, Kinkel K, Hochman MG, Kuhl CK, Kaiser WA, Weinreb JC, Smazal SF, Degani H, Viehweg P, Barclay J, Schnall MD. Development, standardization, and testing of a lexicon for reporting contrast-enhanced breast magnetic resonance imaging studies. J. Magn. Reson. Imaging, 2001; 13: 889-895.
9. Malich A, Fischer DR, Wurdinger S, Boettcher J, Marx C, Facius M, Kaiser WA. Potential MRI interpretation model: differentiation of benign from malignant breast masses. Am. J. Roentgenol. 2005; 185: 964-970.
10. Haddadin IS, McIntosh A, Meisamy S, Corum C, Styczynski Snider AL, Powell NJ, Nelson MT, Yee D, Garwood M, Bolan PJ. Metabolite quantification and high-field MRS in breast cancer. NMR Biomed. 2007; 22: 65-76.
11. Mountford C, Ramadan S, Stanwell P, Malycha P. Proton MRS of the breast in the clinical setting. NMR Biomed. 2008; 22: 54-64.
12. Tse GM, Yeung DK, King AD, Cheung HS, Yang WT. In vivo proton magnetic resonance spectroscopy of breast lesions: an update. Breast Cancer Res. Treat. 2007; 104: 249-255.
13. 1H MR spectroscopy using water as an internal reference at 1.5T. Magma, 2006; 19: 96-104.
14. 1H MRS at 1.5T. Eur. Radiol. 2005; 15: 1037-1043.
15. Yang C, Richardson AD, Smith JW, Osterman A. Comparative metabolomics of breast cancer. Pac. Symp. Biocomput. 2007; 12: 181-192.
16. 1H MR spectroscopy. Radiology, 2009; 251: 653-662.
17. Sardanelli F, Fausto A, Di Leo G, de Nijs R, Vorbuchner M, Podo F. In vivo proton MR spectroscopy of the breast using the total choline peak integral as a marker of malignancy. Am. J. Roentgenol. 2009; 192: 1608-1617.
18. 1H) MR spectroscopy. Radiology, 2007; 245: 80-87.
19. 1H MR spectroscopy of invasive ductal carcinoma: correlations with FDG PET and histologic prognostic factors. Am. J. Roentgenol. 2010; 194: 1384-1390.
20. 1H-magnetic resonance spectroscopy of breast cancer pre- and postgadolinium administration. Invest. Radiol. 2005; 40: 405-411.
21. Lenkinski RE, Wang X, Elian M, Goldberg SN. Interaction of gadolinium-based MR contrast agents with choline: implications for MR spectroscopy (MRS) of the breast. Magn. Reson. Med. 2009; 61: 1286-1292.
22. Murphy PS, Leach MO, Rowland IJ. The effects of paramagnetic contrast agents on metabolite protons in aqueous solution. Phys. Med. Biol. 2002; 47: N53-59.
23. 1H MRS. J. Magn. Reson. Imaging, 2008; 28: 1201-1208.
24. Naressi A, Couturier C, Devos JM, Janssen M, Mangeat C, de Beer R, Graveron-Demilly D. Java-based graphical user interface for the MRUI quantitation package. Magma, 2001; 12: 141-152.
25. Vanhamme L, van den Boogaart A, Van Huffel S. Improved method for accurate and efficient quantification of MRS data with use of prior knowledge. J. Magn. Reson. 1997; 129: 35-43.
26. Nilsson S, Wikstrom M, Ericsson A, Wikstrom G, Waldenstrom A, Oksendal A, Hemmingsson A. MR imaging of double-contrast enhanced porcine myocardial infarction. Correlation with microdialysis. Acta Radiol. 1995; 36: 346-352.
27. 1H MRS) at 1.5T and higher fields. 4th International Congress on MR-Mammography, Jena, Germany, 2006. Eur. Radiol. 2006; 16(suppl. 5): E8-E9.
28. 1H T1 and T2 measurements of the MR imaging contrast agents Gd-DTPA and Gd-DTPA BMA at 1.5T. Eur. Radiol. 1997; 7: 264-274.
29. 1H MRS. Proceedings of the 19th Annual Meeting ISMRM, Stockholm, Sweden, 2010; 18.
30. Giskeodegard GF, Grinde MT, Sitter B, Axelson DE, Lundgren S, Fjosne HE, Dahl S, Gribbestad IS, Bathen TF. Multivariate modeling and prediction of breast cancer prognostic factors using MR metabolomics. J. Proteome Res. 2010; 9: 972-979.
31. Mountford CE, Somorjai RL, Malycha P, Gluch L, Lean C, Russell P, Barraclough B, Gillett D, Himmelreich U, Dolenko B, Nikulin AE, Smith IC. Diagnosis and prognosis of breast cancer by magnetic resonance spectroscopy of fine-needle aspirates analysed using a statistical classification strategy. Br. J. Surg. 2001; 88: 1234-1240.
32. 1H MR spectroscopy using the external standard method. J. Magn. Reson. Imaging, 2010; 31: 895-902.